KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATFurniture, Fixtures and OtherLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Boston Scientific (BSX) Cost of Revenue (2016 - 2025)

Boston Scientific's Cost of Revenue history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 142.79% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $6.2 billion, up 18751.52%, while the annual FY2025 figure was $6.2 billion, 18751.52% up from the prior year.
  • Cost of Revenue for Q4 2025 was $1.6 billion at Boston Scientific, up from $1.5 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.2 billion in Q4 2023 and bottomed at -$3.8 billion in Q4 2024.
  • The 5-year median for Cost of Revenue is $1.1 billion (2023), against an average of $673.6 million.
  • The largest annual shift saw Cost of Revenue surged 22737.5% in 2021 before it plummeted 398.15% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $972.0 million in 2021, then crashed by 398.15% to -$2.9 billion in 2022, then surged by 177.16% to $2.2 billion in 2023, then tumbled by 268.07% to -$3.8 billion in 2024, then skyrocketed by 142.79% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Cost of Revenue are $1.6 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.6 billion (Q2 2025).